Why do cyclo-oxygenase-2 inhibitors cause cardiovascular events?
- 25 January 2002
- journal article
- editorial
- Published by Elsevier in Journal of the American College of Cardiology
- Vol. 39 (3) , 521-522
- https://doi.org/10.1016/s0735-1097(01)01749-1
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Risk of Cardiovascular Events Associated With Selective COX-2 InhibitorsJAMA, 2001
- The Pharmacology of a New Nitric Oxide Donor: B-NODBiochemical and Biophysical Research Communications, 2000
- New look at myocardial infarction: toward a better aspirinCardiovascular Research, 1999
- Production of Prostanoids and Nitric Oxide by Infarcted Heartin Situand the Effect of AspirinBiochemical and Biophysical Research Communications, 1999
- Prostaglandin Endoperoxide H Synthases (Cyclooxygenases)-1 and −2Journal of Biological Chemistry, 1996
- The arachidonic acid metabolic capacity of canine myocardium is increased during healing of acute myocardial infarction.Circulation Research, 1982
- Prostaglandin and thromboxane production by human and guinea-pig macrophages and leucocytesProstaglandins, 1979
- A novel prostaglandin is the major product of arachidonic acid metabolism in rabbit heart.Proceedings of the National Academy of Sciences, 1977
- Prostaglandin release by the isolated perfused rabbit heartProstaglandins, 1973
- Prostaglandin-Like Substances Appearing in Canine Renal Venous Blood During Renal IschemiaCirculation Research, 1970